Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BRM421 in Dry Eye Syndrome
NCT03066219Phase 2Completed
- Sponsor
- BRIM Biotechnology, Inc.
- Start
- Feb 2017
- Primary completion
- May 2017
- Modality
- Modified Peptides, Native Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of BRM421 in dry eye syndrome (DED), sponsored by BRIM Biotechnology, Inc.. Started Feb 2017; status: completed.
02
Drugs
BRM421
03
Conditions
dry eye syndrome (DED)
Beyond the preview
Go deeper on NCT03066219.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03066219.